Fort Washington Investment Advisors Inc. OH Has $3.36 Million Stake in Cencora, Inc. (NYSE:COR)

Fort Washington Investment Advisors Inc. OH trimmed its holdings in Cencora, Inc. (NYSE:COR) by 29.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,094 shares of the company’s stock after selling 5,024 shares during the period. Fort Washington Investment Advisors Inc. OH’s holdings in Cencora were worth $3,363,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in COR. Norges Bank acquired a new stake in shares of Cencora in the fourth quarter valued at approximately $478,309,000. Bank of America Corp DE lifted its position in shares of Cencora by 62.3% in the fourth quarter. Bank of America Corp DE now owns 5,193,807 shares of the company’s stock valued at $1,166,944,000 after buying an additional 1,994,256 shares during the last quarter. Castlekeep Investment Advisors LLC acquired a new stake in shares of Cencora in the fourth quarter valued at approximately $399,508,000. GAMMA Investing LLC lifted its position in shares of Cencora by 43,561.9% in the first quarter. GAMMA Investing LLC now owns 1,598,461 shares of the company’s stock valued at $444,516,000 after buying an additional 1,594,800 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Cencora during the 4th quarter worth approximately $322,460,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Cencora

In other news, CEO Robert P. Mauch sold 4,969 shares of Cencora stock in a transaction on Monday, April 21st. The stock was sold at an average price of $289.33, for a total value of $1,437,680.77. Following the transaction, the chief executive officer now owns 47,582 shares in the company, valued at approximately $13,766,900.06. This trade represents a 9.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Chairman Steven H. Collis sold 14,578 shares of Cencora stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total value of $3,928,916.78. Following the completion of the transaction, the chairman now owns 317,913 shares in the company, valued at approximately $85,680,732.63. The trade was a 4.38% decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,253 shares of company stock valued at $10,582,297 in the last three months. Corporate insiders own 10.80% of the company’s stock.

Cencora Price Performance

Shares of NYSE COR opened at $295.12 on Friday. The stock has a market capitalization of $57.20 billion, a PE ratio of 41.98, a P/E/G ratio of 1.31 and a beta of 0.58. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The business has a fifty day moving average price of $287.24 and a two-hundred day moving average price of $261.65. Cencora, Inc. has a fifty-two week low of $218.65 and a fifty-two week high of $309.35.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating the consensus estimate of $4.07 by $0.35. The firm had revenue of $75.50 billion during the quarter, compared to analysts’ expectations of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.80 EPS. As a group, equities analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 annualized dividend and a yield of 0.75%. Cencora’s dividend payout ratio is presently 25.52%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on COR shares. Wells Fargo & Company raised Cencora from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $274.00 to $337.00 in a report on Tuesday, June 3rd. Wall Street Zen raised Cencora from a “hold” rating to a “buy” rating in a report on Wednesday, March 12th. Morgan Stanley set a $288.00 price target on Cencora in a report on Tuesday, April 15th. UBS Group lifted their price target on Cencora from $298.00 to $335.00 and gave the stock a “buy” rating in a report on Tuesday, April 29th. Finally, Citigroup lifted their price target on Cencora from $330.00 to $355.00 and gave the stock a “buy” rating in a report on Thursday, May 8th. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $306.91.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.